OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Adverse Cardiovascular Complications following prescription of programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors: a propensity-score matched Cohort Study with competing risk analysis
Jiandong Zhou, Sharen Lee, Ishan Lakhani, et al.
Cardio-Oncology (2022) Vol. 8, Iss. 1
Open Access | Times Cited: 15
Jiandong Zhou, Sharen Lee, Ishan Lakhani, et al.
Cardio-Oncology (2022) Vol. 8, Iss. 1
Open Access | Times Cited: 15
Showing 15 citing articles:
Immune checkpoints in cardiac physiology and pathology: therapeutic targets for heart failure
Tamás G. Gergely, Zsófia D. Drobni, Marinos Kallikourdis, et al.
Nature Reviews Cardiology (2024) Vol. 21, Iss. 7, pp. 443-462
Closed Access | Times Cited: 12
Tamás G. Gergely, Zsófia D. Drobni, Marinos Kallikourdis, et al.
Nature Reviews Cardiology (2024) Vol. 21, Iss. 7, pp. 443-462
Closed Access | Times Cited: 12
Achilles’ Heel of currently approved immune checkpoint inhibitors: immune related adverse events
Ting Yan, Yu Lun, Jiwen Zhang, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 8
Ting Yan, Yu Lun, Jiwen Zhang, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 8
Immune-related adverse events with PD-1/PD-L1 inhibitors: insights from a real-world cohort of 2523 patients
Ting Yan, Minghui Long, Chaoyi Liu, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
Ting Yan, Minghui Long, Chaoyi Liu, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
ICIs-Related Cardiotoxicity in Different Types of Cancer
Mei Dong, Ting Yu, Zhenzhen Zhang, et al.
Journal of Cardiovascular Development and Disease (2022) Vol. 9, Iss. 7, pp. 203-203
Open Access | Times Cited: 18
Mei Dong, Ting Yu, Zhenzhen Zhang, et al.
Journal of Cardiovascular Development and Disease (2022) Vol. 9, Iss. 7, pp. 203-203
Open Access | Times Cited: 18
Association between immune checkpoint inhibitors and myocardial infarction in Asians: A population‐based self‐controlled case series
Jeffrey Shi Kai Chan, Pias Tang, Teddy Tai Loy Lee, et al.
Cancer Medicine (2023) Vol. 12, Iss. 8, pp. 9541-9546
Open Access | Times Cited: 11
Jeffrey Shi Kai Chan, Pias Tang, Teddy Tai Loy Lee, et al.
Cancer Medicine (2023) Vol. 12, Iss. 8, pp. 9541-9546
Open Access | Times Cited: 11
Prognostic value of cardiovascular magnetic resonance in immune checkpoint inhibitor‐associated myocarditis: A systematic review and meta‐analysis
Wenhua Song, Nan Zhang, Tonglian Lv, et al.
Cancer Innovation (2024) Vol. 3, Iss. 3
Open Access | Times Cited: 3
Wenhua Song, Nan Zhang, Tonglian Lv, et al.
Cancer Innovation (2024) Vol. 3, Iss. 3
Open Access | Times Cited: 3
Cardiovascular adverse events induced by immune checkpoint inhibitors: A real world study from 2018 to 2022
Si Wu, Hansheng Bai, Ling Zhang, et al.
Frontiers in Cardiovascular Medicine (2022) Vol. 9
Open Access | Times Cited: 15
Si Wu, Hansheng Bai, Ling Zhang, et al.
Frontiers in Cardiovascular Medicine (2022) Vol. 9
Open Access | Times Cited: 15
Risk of diabetes mellitus among users of immune checkpoint inhibitors: A population‐based cohort study
Jeffrey Shi Kai Chan, Sharen Lee, Dicken Kong, et al.
Cancer Medicine (2023) Vol. 12, Iss. 7, pp. 8144-8153
Open Access | Times Cited: 8
Jeffrey Shi Kai Chan, Sharen Lee, Dicken Kong, et al.
Cancer Medicine (2023) Vol. 12, Iss. 7, pp. 8144-8153
Open Access | Times Cited: 8
Cardiovascular adverse events and immune-related adverse events associated with PD-1/PD-L1 inhibitors for head and neck squamous cell carcinoma (HNSCC)
Adila Abulizi, Guang-Peng Yan, Qian Xu, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 2
Adila Abulizi, Guang-Peng Yan, Qian Xu, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 2
Effectiveness of sacubitril-valsartan in patients with cancer therapy-related cardiac dysfunction: a systematic review of clinical and preclinical studies
André Rodrigues Durães, Yasmin de Souza Lima Bitar, Mansueto Gomes Neto, et al.
Minerva Medica (2022) Vol. 113, Iss. 3
Closed Access | Times Cited: 11
André Rodrigues Durães, Yasmin de Souza Lima Bitar, Mansueto Gomes Neto, et al.
Minerva Medica (2022) Vol. 113, Iss. 3
Closed Access | Times Cited: 11
Liver Immune-related Adverse Effects of Programmed Cell Death 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Inhibitors: A Propensity Score Matched Study with Competing Risk Analyses
Jiandong Zhou, Yau-Lam Alex Chau, Jasper Yoo, et al.
Clinical Oncology (2022) Vol. 34, Iss. 7, pp. e316-e317
Closed Access | Times Cited: 11
Jiandong Zhou, Yau-Lam Alex Chau, Jasper Yoo, et al.
Clinical Oncology (2022) Vol. 34, Iss. 7, pp. e316-e317
Closed Access | Times Cited: 11
Evaluating the effect of PD-1 inhibitors on left ventricular function in lung cancer with noninvasive myocardial work
Xia Li, Chujun Wang, Ruirui Kang, et al.
Quantitative Imaging in Medicine and Surgery (2023) Vol. 13, Iss. 5, pp. 3241-3254
Open Access | Times Cited: 2
Xia Li, Chujun Wang, Ruirui Kang, et al.
Quantitative Imaging in Medicine and Surgery (2023) Vol. 13, Iss. 5, pp. 3241-3254
Open Access | Times Cited: 2
Cardiovascular Adverse Events and Immune-related Adverse Events Associated with PD-1/PD-L1 Inhibitors for Head and Neck Squamous Cell Carcinoma (HNSCC): A Real-world study (RWS) by Bayesian Disproportional Analysis Based on the FDA Adverse Event Reporting System (FAERS)
Adila Abulizi, Guang-Peng Yan, Qian Xu, et al.
Research Square (Research Square) (2024)
Open Access
Adila Abulizi, Guang-Peng Yan, Qian Xu, et al.
Research Square (Research Square) (2024)
Open Access
Association among major adverse cardiovascular events with immune checkpoint inhibitors: A systematic review and meta‐analysis
Haixia Li, Yanfei Zheng, Bin Li, et al.
Journal of Internal Medicine (2024)
Open Access
Haixia Li, Yanfei Zheng, Bin Li, et al.
Journal of Internal Medicine (2024)
Open Access
Editorial: Novel phenotyping and risk stratification strategies for heart failure
Jeffrey Shi Kai Chan, Ana Ciobanu, Ying Liu, et al.
Frontiers in Cardiovascular Medicine (2023) Vol. 9
Open Access
Jeffrey Shi Kai Chan, Ana Ciobanu, Ying Liu, et al.
Frontiers in Cardiovascular Medicine (2023) Vol. 9
Open Access
